摘要
目的探讨舍曲林联合喹硫平治疗强迫症伴精神病性症状患者的临床疗效和安全性。方法将60例强迫症伴精神病性症状患者根据随机数字表法分为两组，每组30例，观察组口服舍曲林联合喹硫平治疗，对照组单用舍曲林治疗，观察8周。于治疗前及治疗8周末采用Yale—Brown强迫量表、汉密顿焦虑量表、汉密顿抑郁量表、简明精神病量表评定临床疗效，副反应量表评定不良反应。结果治疗8周末，两组Yale—Brown强迫量表、汉密顿焦虑量表、汉密顿抑郁量表、简明精神病量表评分均较治疗前显著下降（P〈0．01），但观察组均较对照组下降更显著（P〈0．05或0．01）；观察组显效率、总有效率显著高于对照组（P〈0．05）。两组不良反应较轻微，观察组嗜睡发生率显著高于对照组，而失眠发生率显著低于对照组（χ^2=4．71、4．71，P〈0．05）。结论舍曲林联合喹硫平治疗强迫症伴精神病性症状患者效果显著，能显著改善患者的强迫、焦虑、抑郁及精神病性症状，安全性高，依从性好，显著优于单用舍曲林。
Objective To explore the efficacy and safety of sertraline combined with quetiapine in the treat- ment of obsessive-compulsive disorder （OCD） patients with psychotic symptoms. Methods Sixty OCD pa- tients with psychotic symptoms were assigned to two groups of 30 ones each according to random digits ta- ble, observation group took orally sertraline plus quetiapine and control group did single sertraline for 8 weeks. Efficacies were assessed with the Yale-Brown Obsessive Compulsive Scale （Y-ROCS）, Hamilton Anxiety Scale （HAMA）, Hamilton Depression Scale （HAMD） and Brief Psychiatric Rating Scale （BPRS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of 8th week. Results At the end of 8th week, the Y-BOCS, HAMA, HAMD and BPRS scores of both groups lowered more significantly compared with pretreatment （P〈0.01）, so did those in observation than in control group （P〈0.05 or 0.01） ; obvious and total effective rate were significantly higher in ob- servation than in control group （P〈0.05）. Adverse reactions of both groups were mild, the incidence of hypersomnia was significantly higher and that of insomnia lower in observation than in control group （χ^2 = 4.71, 4. 71, P〈0. 05）. Conclusion Sertraline combined with quetiapine has an evident effeet, higher safety and better compliance, could improve obsessive-compulsive, anxious, depressive and psychotic symptoms, and has an advantage over single sertraline in the treatment of OCD patients with psychotic symptoms.
出处
《临床心身疾病杂志》
CAS
2012年第5期413-415,共3页
Journal of Clinical Psychosomatic Diseases
